Agreement - August 1, 2018
Enzymatica in new agreement
The company has entered into a distribution agreement with Qualia Pharma for marketing and sales of ColdZyme Mouth Spray on the Greek and Cypriot market. The background to the agreement is that Qualia Pharma acquired Life NLB on March 1, 2018. The distribution agreement that Enzymatica previously had with Life NLB is now being transferred […]
Agreement - July 24, 2018
Xbrane enters co-development agreement
Xbrane and STADA Arzneimittel have entered into a co-development agreement for Xlucane, a Lucentis (ranibizumab) biosimilar. The collaboration is based on a co-development agreement, meaning that the companies will equally contribute to development expenses and share profits from commercialization in a 50/50 split. To enter into this agreement, STADA will make an upfront payment to […]
Agreement - May 28, 2018
Spago Nanomedical in agreement with CTC
The Swedish clinical CRO CTC Clinical Trial Consultants will conduct Spago’s first clinical study with SpagoPix. The aim of the clinical trial is to document safety and MR images in cancer patients. Compilation of clinical study protocol and material for the application for clinical trial with the Swedish Medical Products Agency is in progress. The […]
Agreement - May 25, 2018
Bonesupport signs agreement with Collagen Matrix
The agreement will allow it to expand the company’s US offering with products that are complementary to Cerament, it states. The company will start selling and marketing selected Collagen Matrix bone graft substitute products under its own brand name, and through its own US distribution network in Q4 2018. “Today’s deal with Collagen Matrix is […]
Agreement - May 21, 2018
LIDDS signs agreement with Chinese pharma company
The Uppsala based company has signed a license agreement for Liproca Depot with Jiangsu Ambition Medical, a Chinese pharmaceutical company specializing in global collaborations and in-licensing. Liproca Depot is LIDDS’ injectable cancer drug candidate for local treatment of prostate cancer. LIDDS is receiving a signing fee exceeding USD 1 million followed by milestone payments and […]
Agreement - May 16, 2018
BioLamina and Novo Nordisk enter partnership
BioLamina and collaborators have partnered with Novo Nordisk, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices. Novo Nordisk have announced that they are increasing their commitment to cell therapies, including areas outside of diabetes. The three cell therapy projects they have licensed are all […]
